The target INR range for patients on warfarin therapy varies depending on their condition but is typically between 2.0 and 3.0.

Frequency of testing depends on individual patient needs, but initially, it may be done weekly or bi-weekly until stable, then less frequently thereafter.

Yes, the PT / INR Test can help diagnose various clotting disorders, including those related to liver disease or genetic clotting factor deficiencies.

Medications, dietary changes, liver function, and underlying health conditions can all influence PT / INR results.

Yes, the PT / INR Test is a safe and standard diagnostic procedure used worldwide to monitor blood clotting ability and adjust anticoagulant therapy.

Benefits include accurate diagnosis, targeted treatment for ureteral conditions, minimal invasiveness, and quick recovery.

A Holter monitor is a portable device used to continuously record the electrical activity of the heart over 24 to 48 hours, capturing data during daily activities.

A Holter monitor helps detect and diagnose irregular heart rhythms (arrhythmias) that may not be captured during a standard ECG.

The monitor is attached to the patient with electrodes placed on the chest. It records heartbeats continuously while the patient carries out normal activities.

Patients experiencing symptoms such as palpitations, dizziness, fainting, or irregular heartbeats may require Holter monitoring to assess their heart’s electrical activity over an extended period.

Holter monitoring typically lasts 24 to 48 hours, depending on the doctor’s recommendation and the specific monitoring objectives.